Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
AbbVie’s Humira is topping industry sales, but by 2025, the drug will fall to the No. 6 spot in best-selling meds, according to a new forecast from GlobalData. Analysts expect Merck’s Keytruda to reach $22.5B in 2025 sales, becoming the new industry leader. See how GlobalData’s forecast affects the rest of the rankings in the chart below:
